Kaixin Auto stock soars on $15M acquisition deal

Investing.com -- Uber Technologies Inc (NYSE:UBER) stock rose 2% in premarket trading Wednesday, while Avride owner Nebius Group NV (AMS:NBIS) gained 1.4% after the companies announced the launch of robotaxi services in Dallas.

The new service allows Dallas riders to be matched with an Avride autonomous vehicle when requesting UberX, Uber Comfort, or Uber Comfort Electric rides at no additional cost. The robotaxis will initially operate in a 9-square-mile area covering Downtown, Uptown, Turtle Creek, and Deep Ellum, with plans for future expansion.

"We’re excited to launch autonomous rides in Dallas with Avride, as we continue to build towards an increasingly electric and autonomous future," said Sarfraz Maredia, Global Head of Autonomous at Uber.

At launch, the robotaxis will have an on-board specialist monitoring behind the wheel, with plans to transition to fully driverless operations in the future. Riders can opt in to increase their chances of being matched with a robotaxi through the Ride Preferences section in the Uber app.

The Dallas launch represents an expansion of the existing partnership between Uber and Avride, building on their autonomous delivery collaboration. Dmitry Polishchuk, CEO at Avride, noted that the company has been focused on robotaxi development "from day one."

The service allows riders to unlock vehicles and start trips directly through the Uber app, with human support available if needed. Uber emphasized that all autonomous vehicles on its network must meet the company’s safety guidelines.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- TD Cowen has named AMD one of its “Best Ideas 2026,” arguing that the upcoming Helios rack-scale platform will “ignite AMD’s AI business” and mark a major turning point for the chipmaker. 

The firm’s analyst Joshua Buchalter reiterated a Buy rating and a $290 price target on the stock, calling the recent sell-off an “attractive entry point.”

According to TD Cowen, “AI compute spending will prove durable and AMD has cemented itself as a winner,” despite rising competitive scrutiny and ongoing debate about an “AI bubble.” 

The analyst stated that AMD is being judged more harshly than rivals, writing that the company “has garnered more bearish sentiment than deserved and than peers.”

Central to their bullish view is the mid-2026 rollout of AMD’s Helios rack and MI450 accelerator. 

TD Cowen argues these products “will mark a key inflection in AMD’s story,” with 4Q26 EPS expected to reach “a >$10 run-rate, or up ~2x… Y/Y and Q/Q.” 

The firm models $89 billion in Instinct sales by 2030, representing a 67% CAGR, adding that even this forecast “falls below AMD’s guided >80% CAGR.”

On investor concerns surrounding AMD’s OpenAI exposure, TD Cowen says the chipmaker is being “unfairly punished,” noting its expected revenue tied to OpenAI in 2027 is “roughly the same” as peers.

Buchalter also points to AMD’s overlooked server and PC businesses, arguing they “remain an important part of AMD’s core business” and will benefit as AI drives demand for real-time inference.

Investing.com -- Tesla (NASDAQ:TSLA) stock rose 1% Wednesday following reports that the Trump administration is planning to accelerate development of the robotics industry, potentially benefiting companies in the automation sector.

According to a Politico report, Commerce Secretary Howard Lutnick has been meeting with robotics industry CEOs and is "all in" on accelerating the sector’s growth. The administration is considering issuing an executive order on robotics next year, sources familiar with the discussions told Politico.

Other robotics-related stocks saw even stronger gains, with Serve Robotics (NASDAQ:SERV) jumping 8%, Richtech Robotics (NASDAQ:RR) surging 11%, and Teradyne (NASDAQ:TER) rising 1%.

The Commerce Department confirmed its commitment to the sector, stating: "We are committed to robotics and advanced manufacturing because they are central to bringing critical production back to the United States."

This robotics initiative follows the administration’s artificial intelligence acceleration plan released five months ago. The Department of Transportation is reportedly preparing to announce a robotics working group, possibly before year-end.

The push has also gained traction in Congress, where Republicans attempted to include an amendment in the National Defense Authorization Act that would have created a national robotics commission. While that amendment wasn’t included in the final bill, other legislative efforts are reportedly underway.

Investing.com -- Capricor Therapeutics (NASDAQ:CAPR) stock surged 14.6% in Wednesday’s premarket trading after the biotechnology company announced positive topline results from its pivotal Phase 3 HOPE-3 trial for Deramiocel, its cell therapy for Duchenne muscular dystrophy (DMD).

The randomized, double-blind, placebo-controlled study met its primary endpoint measuring upper limb function (PUL v2.0) with a 54% slowing of disease progression compared to placebo (p=0.029). The trial also achieved statistical significance in its key secondary endpoint measuring left ventricular ejection fraction (LVEF), showing a 91% slowing of cardiac function decline (p=0.041).

The 12-month study involved 106 participants across 20 U.S. clinical sites, with patients receiving either Deramiocel or placebo every three months. The average participant age was approximately 15 years, with over 75% having a clinical diagnosis of cardiomyopathy at baseline.

"HOPE-3 delivered strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy, demonstrating statistically significant improvements in both skeletal and cardiac function," said Linda Marbán, CEO of Capricor.

The company plans to use these results to address a Complete Response Letter previously received from the FDA, with expectations that the data will support regulatory approval.

However, not all observers were convinced by the results. Investor Martin Shkreli, who holds a short position in the company, criticized the findings, saying: "I think CAPR failed. it doesn’t say prespecified primary endpoint. they’re taking the primary endpoint SCALE and doing post-hoc analyses on it! 1.2 point improvement on 42 point scale is a 3% improvement vs. placebo -- that can’t be stat sig"

Capricor maintained that Deramiocel showed a favorable safety and tolerability profile consistent with previous clinical experience. The company plans to submit detailed results for presentation at future scientific meetings and for publication in peer-reviewed journals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.